Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review
BackgroundImmune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare.Case pr...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.973421/full |
| _version_ | 1811305031428734976 |
|---|---|
| author | Qiaoyun Tan Lichao Liu Yu Huang Xiaorong Dong Lingjuan Chen |
| author_facet | Qiaoyun Tan Lichao Liu Yu Huang Xiaorong Dong Lingjuan Chen |
| author_sort | Qiaoyun Tan |
| collection | DOAJ |
| description | BackgroundImmune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare.Case presentationA 78-year-old man with squamous lung cancer, with brain metastasis, was treated with pembrolizumab and albumin-bound paclitaxel as first-line treatment for one cycle and changed to pembrolizumab plus anlotinib at the second cycle. After two therapy cycles, grade 4 neutropenia developed, which mainly contributed to irAEs. The patient was started on granulocyte colony-stimulating factor (G-CSF) but did not improve; he was then treated with corticosteroids, and neutrophil counts gradually returned to normal levels. However, the patient eventually died because of neurological problems.ConclusionGrade 4 neutropenia associated with ICI, although rare, is often severe and presents with infectious complications; it needs to be diagnosed early, and clinicians should ensure prompt and proper management to such patients. |
| first_indexed | 2024-04-13T08:18:12Z |
| format | Article |
| id | doaj.art-a707008e76634f43bc6152fbea74dc5b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T08:18:12Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-a707008e76634f43bc6152fbea74dc5b2022-12-22T02:54:43ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-11-011210.3389/fonc.2022.973421973421Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature reviewQiaoyun TanLichao LiuYu HuangXiaorong DongLingjuan ChenBackgroundImmune checkpoint inhibitors, including anti-PD-1 therapies, have prolonged overall survival in patients with a variety of cancers, and immunotherapy is sometimes associated with immune-related adverse events (irAEs); however, hematological toxicity, especially neutropenia, is rare.Case presentationA 78-year-old man with squamous lung cancer, with brain metastasis, was treated with pembrolizumab and albumin-bound paclitaxel as first-line treatment for one cycle and changed to pembrolizumab plus anlotinib at the second cycle. After two therapy cycles, grade 4 neutropenia developed, which mainly contributed to irAEs. The patient was started on granulocyte colony-stimulating factor (G-CSF) but did not improve; he was then treated with corticosteroids, and neutrophil counts gradually returned to normal levels. However, the patient eventually died because of neurological problems.ConclusionGrade 4 neutropenia associated with ICI, although rare, is often severe and presents with infectious complications; it needs to be diagnosed early, and clinicians should ensure prompt and proper management to such patients.https://www.frontiersin.org/articles/10.3389/fonc.2022.973421/fullneutropeniapembrolizumablung canceradverse effectinfection |
| spellingShingle | Qiaoyun Tan Lichao Liu Yu Huang Xiaorong Dong Lingjuan Chen Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review Frontiers in Oncology neutropenia pembrolizumab lung cancer adverse effect infection |
| title | Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review |
| title_full | Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review |
| title_fullStr | Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review |
| title_full_unstemmed | Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review |
| title_short | Case report: A rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review |
| title_sort | case report a rare case of neutropenia caused by pembrolizumab in squamous lung cancer and literature review |
| topic | neutropenia pembrolizumab lung cancer adverse effect infection |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.973421/full |
| work_keys_str_mv | AT qiaoyuntan casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview AT lichaoliu casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview AT yuhuang casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview AT xiaorongdong casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview AT lingjuanchen casereportararecaseofneutropeniacausedbypembrolizumabinsquamouslungcancerandliteraturereview |